The human eye is incredibly complex with meticulously designed structure to maintain our vision under different conditions and environment

Understanding the Problem

Structurally, there are both static and dynamic barriers to selectively control the crossing of compounds in and out of our eyes. The existence of these barriers, however, makes topical drug delivery to the posterior segment very challenging. As a result, invasive methods such as injections are often needed for drug delivery for a wide range of posterior diseases. 

​Ultrasound-mediated Drug Delivery[1]

With Opharmic’s proprietary ultrasound technology, therapeutics can be delivered non-invasively via the sclera, a novel route of administration. Primarily based on the effects of cavitation and acoustic microstreaming, the dual-mechanism technology help create fluid flow to allow the crossing of therapeutics into the eye.

[1] Suen et al., Ultrasound-Mediated Transscleral Delivery of Macromolecules to the Posterior Segment of Rabbit Eye In Vivo, IOVS, 2013, Vol.54, 4358-4365​

 Publications & Presentations 

Suen et al., Ultrasound-Mediated Transscleral Delivery of Macromolecules to the Posterior Segment of Rabbit Eye In Vivo, IOVS, 2013, Vol.54, 4358-4365​

Suen et al., Examination of effects of low-frequency ultrasound on scleral permeability and collagen network, Ultrasound Med. Biol., 2016 Nov; 42(11):2650-2661​

Chau et al., Ultrasound-enhanced penetration through sclera depends on frequency of sonication and size of macromolecules, Eur. J. Pharm. Sci., 2017 Mar 30; 100:273-279​

Internal Development Pipeline

We are currently developing two proprietary ocular drug delivery systems that address both the posterior and anterior segments, with safety and efficacy well-demonstrated in preclinical studies.

Partnered Development Programs

Coming soon.